State-of-the-art strategies to prioritize Mycobacterium tuberculosis drug targets for drug discovery using a subtractive genomics approach
Tuberculosis remains one of the causes of death from a single infectious bacterium. The inappropriate use of antibiotics and patients’ non-compliance among other factors drive the emergence of drug-resistant tuberculosis. Multidrug-resistant and extensively drug-resistant strains of tuberculosis pos...
Main Authors: | Adetutu Akinnuwesi, Samuel Egieyeh, Ruben Cloete |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Drug Discovery |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fddsv.2023.1254656/full |
Similar Items
-
Editorial: Drug-resistant Mycobacterium tuberculosis
by: Helena I. M. Boshoff, et al.
Published: (2023-05-01) -
How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery
by: Amala Bhagwat, et al.
Published: (2022-09-01) -
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
by: Aaron Goff, et al.
Published: (2020-07-01) -
The Patterns of Conversion to Anti-Tuberculosis Drug Resistance in Mycobacterium tuberculosis
by: Moo-Sang Chong, et al.
Published: (2022-06-01) -
Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection
by: Christian Shleider Carnero Canales, et al.
Published: (2023-09-01)